Search Results - "Roche, Henri"

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation by Litton, Jennifer K, Rugo, Hope S, Ettl, Johannes, Hurvitz, Sara A, Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Yerushalmi, Rinat, Mina, Lida A, Martin, Miguel, Roché, Henri, Im, Young-Hyuck, Quek, Ruben G.W, Markova, Denka, Tudor, Iulia C, Hannah, Alison L, Eiermann, Wolfgang, Blum, Joanne L

“…Among patients with breast cancer and germline mutations in the BRCA DNA repair pathway genes, the poly(adenosine diphosphate–ribose) inhibitor talazoparib…”
Get full text

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment by THOMAS, Eva S, GOMEZ, Henry L, BINGHE XU, CAMPONE, Mario, LERZO, Guillermo L, PECK, Ronald A, MUKHOPADHYAY, Pralay, VAHDAT, Linda T, ROCHE, Henri H, LI, Rubi K, CHUNG, Hyun-Cheol, FEIN, Luis E, CHAN, Valorie F, JASSEM, Jacek, PIVOT, Xavier B, KLIMOVSKY, Judith V, HURTADO DE MENDOZA, Fernando

“…Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent…”
Get full text

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer by LIN, Nancy U, DIERAS, Véronique, LOIBL, Sibylle, GORI, Stefania, WARDLEY, Andrew, YARDLEY, Denise, BRUFSKY, Adam, BLUM, Joanne L, RUBIN, Stephen D, DHARAN, Bernie, STEPLEWSKI, Klaudia, ZEMBRYKI, Denise, PAUL, Devchand, OLIVA, Cristina, ROYCHOWDHURY, Debasish, PAOLETTI, Paolo, WINER, Eric P, LOSSIGNOL, Dominique, CHRISTODOULOU, Christos, STEMMLER, Hans-Joachim, ROCHE, Henri, LIU, Minetta C, GREIL, Richard, CIRUELOS, Eva

“…Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS)…”
Get full text

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study by Pierga, Jean-Yves, Prof, Petit, Thierry, Prof, Delozier, Thierry, MD, Ferrero, Jean-Marc, Prof, Campone, Mario, MD, Gligorov, Joseph, MD, Lerebours, Florence, MD, Roché, Henri, Prof, Bachelot, Thomas, MD, Charafe-Jauffret, Emmanuelle, Prof, Pavlyuk, Maria, MD, Kraemer, Sandrine, MSc, Bidard, François-Clément, MD, Viens, Patrice, Prof

“…Summary Background Bevacizumab and trastuzumab are efficacious for treatment of advanced or HER2-positive metastatic breast cancer; however, few data exist for…”
Get full text

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial by ROCHE, Henri, FUMOLEAU, Pierre, VIENS, Patrice, MONNIER, Alain, VINDEVOGHEL, Anita, CAMPONE, Mario, GOUDIER, Marie-Josèphe, BONNETERRE, Jacques, FERRERO, Jean-Marc, MARTIN, Anne-Laure, GENEVE, Jean, ASSELAIN, Bernard, SPIELMANN, Marc, CANON, Jean-Luc, DELOZIER, Thierry, SERIN, Daniel, SYMANN, Michel, KERBRAT, Pierre, SOULIE, Patrick, EICHLER, Francoise

“…The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by…”
Get full text

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer by BASELGA, José, MARTINS SEGALLA, José Getúlio, LLOMBART, Antonio, GARICOCHEA, Bernardo, CLIMENT DURAN, Miguel Angel, GEHM HOFF, Paulo Marcelo, ESPIE, Marc, GEMEINDER DE MORAES, Andre Augusto, ALBUQUERQUE RIBEIRO, Ronaldo, MATHIAS, Clarissa, GIL GIL, Miguel, OJEDA, Belén, ROCHE, Henri, MORALES, Josefa, KWON RO, Sunhee, LI, Shell, COSTA, Frederico, DEL GIGLIO, Auro, PINCZOWSKI, Hélio, CIRUELOS, Eva M, CABRAL FILHO, Sebastião, GOMEZ, Patricia, VAN EYLL, Brigitte, BERMEJO, Begoña

“…Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed…”
Get full text

DNA polymerase θ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability by Lemée, Fanny, Bergoglio, Valérie, Fernandez-Vidal, Anne, Machado-Silva, Alice, Pillaire, Marie-Jeanne, Bieth, Anne, Gentil, Catherine, Baker, Lee, Martin, Anne-Laure, Leduc, Claire, Lam, Elena, Magdeleine, Eddy, Filleron, Thomas, Oumouhou, Naïma, Kaina, Bernd, Seki, Mineaki, Grimal, Fanny, Lacroix-Triki, Magali, Thompson, Alastair, Roché, Henri, Bourdon, Jean-Christophe, Wood, Richard D., Hoffmann, Jean-Sébastien, Cazaux, Christophe, Hanawalt, Philip C.

“…"Replicative stress" is one of the main factors underlying neoplasia from its early stages. Genes involved in DNA synthesis may therefore represent an…”
Get full text

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer by Puszkiel, Alicja, Arellano, Cécile, Vachoux, Christelle, Evrard, Alexandre, Le Morvan, Valérie, Boyer, Jean‐Christophe, Robert, Jacques, Delmas, Caroline, Dalenc, Florence, Debled, Marc, Venat‐Bouvet, Laurence, Jacot, William, Dohollou, Nadine, Bernard‐Marty, Chantal, Laharie‐Mineur, Hortense, Filleron, Thomas, Roché, Henri, Chatelut, Etienne, Thomas, Fabienne, White‐Koning, Melanie

“…Variations in clinical response to tamoxifen (TAM) may be related to polymorphic cytochromes P450 (CYPs) involved in forming its active metabolite endoxifen…”
Get full text

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens by VALERO, Vicente, FORBES, John, FUMOLEAU, Pierre, ROLSKI, Janusz, MRSIC-KRMPOTIC, Zrinka, JAGIELLO-GRUSZFELD, Agnieszka, RIVA, Alessandro, BUYSE, Marc, TAUPIN, Henry, SAUTER, Guido, PRESS, Michael F, SLAMON, Dennis J, PEGRAM, Mark D, PIENKOWSKI, Tadeusz, EIERMANN, Wolfgang, VON MINCKWITZ, Gunter, ROCHE, Henri, MARTIN, Miguel, CROWN, John, MACKEY, John R

“…Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel,…”
Get full text

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup by D'Hondt, Véronique, Canon, Jean-Luc, Roca, Lise, Levy, Christelle, Pierga, Jean-Yves, Le Du, Fanny, Campone, Mario, Desmoulins, Isabelle, Goncalves, Anthony, Debled, Marc, Rios, Maria, Ferrero, Jean-Marc, Serin, Daniel, Hardy-Bessard, Anne-Claire, Piot, Gilles, Brain, Etienne, Dohollou, Nadine, Orfeuvre, Hubert, Lemonnier, Jerome, Roché, Henri, Delaloge, Suzette, Dalenc, Florence

“…We conducted a double-randomised phase III trial to evaluate a concomitant taxane-anthracycline regimen in node-positive breast cancer and the efficacy of…”
Get full text

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial by Roca, Lise, Diéras, Véronique, Roché, Henri, Lappartient, Emmanuelle, Kerbrat, Pierre, Cany, Laurent, Chieze, Stéphanie, Canon, Jean-Luc, Spielmann, Marc, Penault-Llorca, Frédérique, Martin, Anne-Laure, Mesleard, Christel, Lemonnier, Jérôme, de Cremoux, Patricia

“…The purpose of this study was to investigate, in the context of a prospective node-positive-breast cancer trial HER2 containing-regimen (UNICANCER-PACS 04…”
Get full text

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer by Llombart-Cussac, Antonio, Bermejo, Begoña, Villanueva, Cristian, Delaloge, Suzette, Morales, Serafín, Balmaña, Judith, Amillano, Kepa, Bonnefoi, Hervé, Casas, Ana, Manso, Luis, Roché, Henri, Gonzalez-Santiago, Santiago, Gavilá, Joaquín, Sánchez-Rovira, Pedro, Di Cosimo, Serena, Harbeck, Nadia, Charpentier, Eric, Garcia-Ribas, Ignacio, Radosevic-Robin, Nina, Aura, Claudia, Baselga, Jose

“…Iniparib is an investigational agent with antitumor activity of controversial mechanism of action. Two previous trials in advanced triple-negative breast…”
Get full text

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer by Campone, Mario, Lacroix-Triki, Magali, Roca, Lise, Spielmann, Marc, Wildiers, Hans, Cottu, Paul, Kerbrat, Pierre, Levy, Christelle, Desmoulins, Isabelle, Bachelot, Thomas, Winston, Tan, Eymard, Jean-Christophe, Uwer, Lionel, Duhoux, Francois P., Verhoeven, Didier, Jaubert, Dominique, Coeffic, David, Orfeuvre, Hubert, Canon, Jean Luc, Asselain, Bernard, Martin, Anne-Laure, Lemonnier, Jerome, Roché, Henri

“…UNICANCER-PACS08 compared adjuvant FEC (5-FU; epirubicin; cyclophosphamide) then docetaxel to FEC then ixabepilone in poor prognosis early breast cancer (BC)…”
Get full text

Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial by BONNETERRE, Jacques, ROCHE, Henri, KERBRAT, Pierre, BREMOND, Alain, FUMOLEAU, Pierre, NAMER, Moïse, GOUDIER, Marie-Josèphe, SCHRAUB, Simon, FARGEOT, Pierre, CHAPELLE-MARCILLAC, Isabelle

“…The French Adjuvant Study Group 05 (FASG-05) showed that fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2 (FEC 100) was superior to…”
Get full text

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study by Tabouret, Emeline, Bertucci, François, Pierga, Jean-Yves, Petit, Thierry, Levy, Christelle, Ferrero, Jean-Marc, Campone, Mario, Gligorov, Joseph, Lerebours, Florence, Roché, Henri, Bachelot, Thomas, van Laere, Steven, Ueno, Naoto T, Toiron, Yves, Finetti, Pascal, Birnbaum, Daniel, Borg, Jean-Paul, Viens, Patrice, Chinot, Olivier, Gonçalves, Anthony

“…Addition of bevacizumab to trastuzumab-based neoadjuvant chemotherapy in HER2-positive inflammatory breast cancer (IBC) was associated with favorable outcome…”
Get full text

Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer by Toffoli, Sébastien, Bar, Isabelle, Abdel-Sater, Fadi, Delrée, Paul, Hilbert, Pascale, Cavallin, Frédéric, Moreau, Fabrice, Van Criekinge, Wim, Lacroix-Triki, Magali, Campone, Mario, Martin, Anne-Laure, Roché, Henri, Machiels, Jean-Pascal, Carrasco, Javier, Canon, Jean-Luc

“…Triple Negative Breast Cancers (TNBC) represent about 12% to 20% of all breast cancers (BC) and have a worse outcome compared to other BC subtypes. TNBC often…”
Get full text

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer by Baselga, José, Zamagni, Claudio, Gómez, Patricia, Bermejo, Begoña, Nagai, Shigenori E., Melichar, Bohuslav, Chan, Arlene, Mángel, Lászlo, Bergh, Jonas, Costa, Frederico, Gómez, Henry L., Gradishar, William J., Hudis, Clifford A., Rapoport, Bernardo L., Roché, Henri, Maeda, Patricia, Huang, Liping, Meinhardt, Gerold, Zhang, Joshua, Schwartzberg, Lee S.

“…A previous randomized phase II trial suggested that sorafenib might enhance the efficacy of capecitabine in patients with metastatic breast cancer. However, in…”
Get full text

Risk adapted chemotherapy for localised Ewing’s sarcoma of bone: The French EW93 study by Gaspar, Nathalie, Rey, Annie, Bérard, Perrine Marec, Michon, Jean, Gentet, Jean Claude, Tabone, Marie Dominique, Roché, Henri, Defachelles, Anne Sophie, Lejars, Odile, Plouvier, Emmanuel, Schmitt, Claudine, Bui, Binh, Boutard, Patrick, Taque, Sophie, Munzer, Martine, Vannier, Jean-Pierre, Plantaz, Dominique, Enz-Werlé, Natacha, Oberlin, Odile

“…Abstract Aim of the study To determine whether a risk factor adapted chemotherapy would improve the outcome of non-metastatic bone Ewing’s sarcoma. Methods…”
Get full text

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106) by Kerbrat, Pierre, Desmoulins, Isabelle, Roca, Lise, Levy, Christelle, Lortholary, Alain, Marre, Alain, Delva, Rémy, Rios, Maria, Viens, Patrice, Brain, Étienne, Serin, Daniel, Edel, Magali, Debled, Marc, Campone, Mario, Mourret-Reynier, Marie-Ange, Bachelot, Thomas, Foucher-Goudier, Marie-Josèphe, Asselain, Bernard, Lemonnier, Jérôme, Martin, Anne-Laure, Roché, Henri

“…Abstract Purpose Optimal duration of adjuvant chemotherapy in the treatment of early-stage breast cancer remained to be investigated rigorously for the…”
Get full text

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study by Diéras, Véronique, Wildiers, Hans, Jassem, Jacek, Dirix, Luc Y, Guastalla, Jean-Paul, Bono, Petri, Hurvitz, Sara A, Gonçalves, Anthony, Romieu, Gilles, Limentani, Steven A, Jerusalem, Guy, Lakshmaiah, K.C, Roché, Henri, Sánchez-Rovira, Pedro, Pienkowski, Tadeusz, Seguí Palmer, Miguel Ángel, Li, Ai, Sun, Yu-Nien, Pickett, Cheryl A, Slamon, Dennis J

“…Abstract Introduction This phase 2 randomized study evaluated trebananib (AMG 386), a peptide-Fc fusion protein that inhibits angiogenesis by neutralizing the…”
Get full text